Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

ConclusionFremanezumab demonstrated sustained efficacy up to 6 months and was well tolerated in patients with episodic migraine or chronic migraine and documented inadequate response to multiple migraine preventive medication classes.Trial registrationClinicalTrials.govNCT03308968 (FOCUS).

http://link.springer.com/10.1186/s10194-021-01279-7

Source: The Journal of Headache and Pain - July 10, 2021 Category: Neurology Source Type: research